drugset / Trial / NCT00789360

Staccato Loxapine Pulmonary Safety in Healthy Volunteers

NCT00789360

Phase 1 Completed 30 enrolled Alexza Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.

Timeline

Start
2008-11
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject loxapine Small molecule 10 mg Inhaled

Indications

No indication recorded.